Shares of First Tracks Biotherapeutics were higher after the company said it would review top-line data from a trial of its treatment for celiac disease on Monday.

The stock rose 15%, to $36.71, in premarket trading. Through Friday's close, shares are up nearly 68% year to date.

The company said late Friday that it will host an investor call and live webcast to review top-line data from the first cohort of an early-stage trial investigating its drug, ANB033, as a treatment for celiac disease.

The call and webcast are scheduled for 8:30 a.m. Eastern on Monday.